The company was founded in 2010 and is located in China Pharmaceutical City, Taizhou, Jiangsu, the first national pharmaceutical high-tech zone. It was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on December 5, 2019. The company focuses on R&D, production and sales of in vitro diagnostic products such as in vitro diagnostic reagents and supporting testing instruments, and has expanded into the field of in vitro testing services to achieve an integrated business model of “reagent+instrument+service”. The company has modern biological technology platforms such as nucleic acid molecular detection reagents, multiple fluorescence quantitative PCR, and dry chemistry. Corporate honors: 2018 Jiangsu Province's Top 100 Most Promising Scientific and Technological Talent Startups, National March 8th Women's Day Social Welfare Award, Model Workers' Home, Caring Enterprise for China's Eugenics Science Western Campaign, Contract-abiding and Credit-worthy Enterprise (2017), etc. In 2023, the company vigorously implemented the brand strategy and was selected for the 2023-2025 list of internationally renowned brands cultivated and developed in Jiangsu Province, and successfully received many honors such as Jiangsu High-profile Trademarks, National AAA Famous Trademark Brands, China Patent Excellence Award, Jiangsu Quality Standard, Taizhou Mayor Quality Award, Taizhou Mayor Quality Award, and Taizhou's “Genuine Goods” Commitment Project.
No Data
No Data